Search

Displaying results 2491 - 2500 of 7452 in total
  1. Drug

    Ambroxol

    go.drugbank.com/drugs/DB06742
    ApprovedInvestigational

    Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin.

    Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway Diseases
  2. Drug

    Elafin

    go.drugbank.com/drugs/DB05161
    Investigational

    Elafin’s ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or

  3. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma.

  4. Drug

    Quercus alba pollen

    go.drugbank.com/drugs/DB10376
    Approved

    Quercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen. … Diagnostic allergenic extracts are primarily indicated for establishing clinical relevance of specific allergens to which the patient has been exposed and the degree of sensitivity the patient has toward

  5. Drug

    Colesevelam

    go.drugbank.com/drugs/DB00930
    ApprovedInvestigational

    Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bil...

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  6. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. … On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

  7. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    It is being studied for the prevention of HIV infection and other sexually transmitted diseases. … PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Cefaloridine

    go.drugbank.com/drugs/DB09008
    ApprovedWithdrawn

    Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    Meningococcal group A polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup A. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis a...

    Mixtures: MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTION, Menveo Powder and Solution for Solution for Injection
  10. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection … Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by